Integral Diagnostics faces worst day in 18 months on disappointing results

Integral Diagnostics

17/02/2023 03:05

** Shares of Australia's Integral Diagnostics  IDX.AX  fall
as much as 16.4% to A$2.63 - set to mark worst day since August
2021, if current losses hold
    ** Healthcare firm posts HY revenue of A$216 mln ($148.00
mln), missing RBC estimates of A$221 mln
    ** Operating NPAT of A$7.8 mln missed consensus estimates of
A$12.2 mln
    ** Co declares interim dividend of 2.5 Australian cents per
share, compared with 4.0 Australian cents per share a year
earlier
    ** Analysts at RBC say they expect the market to focus on
underlying EBITDA level, which is 7% below its estimate
    ** Citi says reported bottom line number also a miss on its
estimate
    ** Stock had risen 7.2% this year, as of last close 
($1 = 1.4594 Australian dollars)
 (Reporting by Rishav Chatterjee in Bengaluru)
 ((Rishav.Chatterjee@thomsonreuters.com;))